| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/31/2002 | WO2002007704A2 Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone |
| 01/31/2002 | WO2002007683A1 Antimicotic nail varnish composition |
| 01/31/2002 | WO2002007673A2 Calcilytic compounds |
| 01/31/2002 | WO2002007671A2 Intracellular delivery system for protein phosphatases and other polypeptides |
| 01/31/2002 | WO2002007670A2 Intracellular delivery system for protein phosphatases |
| 01/31/2002 | WO2001083693A8 Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses |
| 01/31/2002 | WO2001068120A3 Uses of bombesin receptor 3 |
| 01/31/2002 | WO2001064185A3 Method for making, loading and sealing a cell or drug encapsulation device, and such a device |
| 01/31/2002 | WO2001064182A3 Improvements in or relating to the delivery of oral drugs |
| 01/31/2002 | WO2001062784A3 Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer |
| 01/31/2002 | WO2001062299A3 Water-soluble polymer conjugates of artelinic acid |
| 01/31/2002 | WO2001061017A3 Modified cytokines for use in cancer therapy |
| 01/31/2002 | WO2001060416A3 Matrix metalloproteinase inhibitors as targeting components in diagnostic agents |
| 01/31/2002 | WO2001060348A3 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| 01/31/2002 | WO2001052894A3 Nasally administrable cyclic peptide compositions |
| 01/31/2002 | WO2001049272A3 Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
| 01/31/2002 | WO2001049270B1 Odor-masking coating for a pharmaceutical preparation |
| 01/31/2002 | WO2001041736A3 Microchip devices for delivery of molecules and methods of fabrication thereof |
| 01/31/2002 | WO2001039788A3 Methods for targeting cells that express fibroblast growth receptor-3 or-2 |
| 01/31/2002 | WO2001034801A3 Recombinant gelatin in vaccines |
| 01/31/2002 | WO2001022791A3 Controlled release compositions comprising nimesulide |
| 01/31/2002 | WO2001015738A3 Nitric oxide-producing hydrogel materials |
| 01/31/2002 | WO2001013958A3 Drug conjugates and methods of designing the same |
| 01/31/2002 | WO2000072827A9 Porous drug matrices and methods of manufacture thereof |
| 01/31/2002 | WO2000064487A8 Delivery of antimicrobial toxins |
| 01/31/2002 | US20020013497 Alkylation, blocking |
| 01/31/2002 | US20020013485 Cytotoxic agents comprising taxanes and their therapeutic use |
| 01/31/2002 | US20020013484 Water solubility; prodrug containing polyether oligomer |
| 01/31/2002 | US20020013408 Cross-linked polymer compositions and methods for their use |
| 01/31/2002 | US20020013357 Valdecoxib compositions |
| 01/31/2002 | US20020013338 Incorporating stabilizing effective amount of a hydrochloric acid donor to pharmaceutical formulation containing an active component subject to degradation |
| 01/31/2002 | US20020013331 For therapy of pain associated with mucosal damage, such as inflamation, abrasions, ulcerations, lesions, incisions, and trauma |
| 01/31/2002 | US20020013305 Aqueous solvent for corticosteroids |
| 01/31/2002 | US20020013298 Such as multiple sclerosis, by administering antimicrotubule agent: epothilones, discodermolide, deuterium oxide, hexylene glycol, tubercidin, LY-290181, alumimum fluoride, glycine ethyl ester, or ethylene glycol bis(succinimidylsuccinate) |
| 01/31/2002 | US20020013294 Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| 01/31/2002 | US20020013291 Reperfusion injury; 2-Deoxy-6-O-(2-deoxy-4-O-phosphono-3-O-(3-tetradecanoyloxytetradecanoyl)-2 -(3-octadecanoyloxy-tetradecanoylamino)-beta-D-glucopyranosyl)-2-(3 -hexadecanoyloxytetradecanoylamino)-D-glucopyranose |
| 01/31/2002 | US20020013275 Inhibiting stenosis following vascular trauma or disease by administering a conjugate of a vascular smooth muscle binding protein that associates with a cell surface of the vascular smooth muscle coupled to a drug inhibiting cellular activity |
| 01/31/2002 | US20020013273 Method for producing sustained-release formulations |
| 01/31/2002 | US20020013272 Comprising a cyclosporin in a carrier medium of a fatty acid triglyceride and a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester; biavailability; side-effect reductions |
| 01/31/2002 | US20020013266 Polymer stabilized neuropeptides |
| 01/31/2002 | US20020013264 Glycosylaminoglycan (GAG) chains chemically modified with a carbodiimide such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide |
| 01/31/2002 | US20020013263 Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| 01/31/2002 | US20020013003 Site-specific, covalent bioconjugation of proteins |
| 01/31/2002 | US20020012998 Gene transfer composition; for use in the transfection of mammalian cells |
| 01/31/2002 | US20020012931 High specificity marker detection |
| 01/31/2002 | US20020012723 Containing sugar to provide freezing and thawing stability; foods, drinks; treatment of anemia |
| 01/31/2002 | US20020012715 Protecting cell from damage caused by free radicals by administering lipophilic antioxidant comprising vitamin E, beta carotene, extract of Lycopersicum esculentum, hydrophilic antioxidant comprising vitamin c, extract of vitis vinifera |
| 01/31/2002 | US20020012713 Water-soluble complex of an extract of ginkgo biloba, process for the preparation thereof and composition comprising the same |
| 01/31/2002 | US20020012706 Method of making granular pharmaceutical vehicle |
| 01/31/2002 | US20020012705 Polymer constructs |
| 01/31/2002 | US20020012704 Water-insoluble drug particle process |
| 01/31/2002 | US20020012703 Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent |
| 01/31/2002 | US20020012701 Mixture of polyvinyl acetate, polyvinylpyrrolidone, active ingredients, water-soluble polymers or low or high molecular weight lipophilic additives are heated, granulated |
| 01/31/2002 | US20020012700 Portion of pseudoephedrine is contained in core whereby release into environment of use is sustained, cetirizine is contained as immediate-release component; antiallergens, spasmolytics |
| 01/31/2002 | US20020012695 Increased skin permeation of drug, and allows improved drug stability within the adhesive layer |
| 01/31/2002 | US20020012694 For delivery of 7 alpha -methyl-19-nortestosterone (MENT) |
| 01/31/2002 | US20020012691 Time-release agents, therapy in humans, veterinary medicine |
| 01/31/2002 | US20020012679 Process for manufacturing coated gabapentin or pregabalin particles |
| 01/31/2002 | US20020012677 Pharmaceutical composition for treating dysmenorrhea and premature labor |
| 01/31/2002 | US20020012676 For inhibiting gastric acid secretion in mammals and man |
| 01/31/2002 | US20020012674 Bioadhesive complexes of polycarbophil and azole antifungal or antiprotozoal drugs |
| 01/31/2002 | US20020012673 Immunstimulating lipid formulation |
| 01/31/2002 | US20020012649 Lipid composition containing a liquid crystal structure |
| 01/31/2002 | DE10035513A1 Wirkstoffkombinationen bzw. Addukte aus Cyclodextrinen und mindestens einem Chinon und/oder mindestens einem Hydrochinon und Verwendung solcher Wirkstoffkombinationen in kosmetischen Zubereitungen Active compound combinations or adducts of cyclodextrins and at least one quinone and / or at least one hydroquinone and use of such drug combinations in cosmetic preparations |
| 01/31/2002 | DE10034802A1 Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren Stable salts of O-acetylsalicylic acid with basic amino acids |
| 01/31/2002 | DE10033853A1 Transdermal therapeutic system, containing highly dispersed silicon dioxide in matrix or adhesive layer to promote drug permeation through the skin |
| 01/31/2002 | DE10033059A1 New inclusion complexes of benzocaine in gamma-cyclodextrin, useful as non-volatile local anesthetics, e.g. for alleviating surface pain |
| 01/31/2002 | DE10032456A1 Schnell zerfallende Darreichungsform zur Freisetzung von Wirkstoffen im Mundraum oder in Körperhöhlen Rapidly disintegrating dosage form for the delivery of drugs to the oral cavity or into body cavities |
| 01/31/2002 | CA2797652A1 Multi-component biological transport systems |
| 01/31/2002 | CA2417185A1 Multivalent target binding protein |
| 01/31/2002 | CA2416751A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | CA2416608A1 Pharmaceutically active compound |
| 01/31/2002 | CA2416537A1 Calcilytic compounds |
| 01/31/2002 | CA2416488A1 Codon-optimized papilloma virus sequences |
| 01/31/2002 | CA2416404A1 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor |
| 01/31/2002 | CA2416257A1 Compositions and films for capsule manufacture |
| 01/31/2002 | CA2415862A1 Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma |
| 01/31/2002 | CA2415345A1 Linkage of agents using microparticles |
| 01/31/2002 | CA2415131A1 Improved oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea |
| 01/31/2002 | CA2412376A1 Pharmaceutical suspension compositions lacking a polymeric suspending agent |
| 01/31/2002 | CA2410683A1 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs |
| 01/30/2002 | EP1176160A2 Water soluble active sulfones of poly(ethylene glycol) |
| 01/30/2002 | EP1176154A1 Carnosine derivatives, a process for the preparation thereof and pharmaceutical compositions containing them |
| 01/30/2002 | EP1175915A1 A method for preparing resinates |
| 01/30/2002 | EP1175914A2 A resinate composition |
| 01/30/2002 | EP1175913A1 Intramuscular pharmaceutical composition comprising dexibuprofen and uses thereof |
| 01/30/2002 | EP1175912A1 Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
| 01/30/2002 | EP1175908A1 Oleoresin of hypericum perforatum l., method for obtaining said oleoresin and the use thereof |
| 01/30/2002 | EP1175899A1 Starch and lactose granulate |
| 01/30/2002 | EP1175892A1 Use of EP-3 prostaglandins receptor antagonists as cosmetic agent for reducing or stopping hairloss |
| 01/30/2002 | EP1175498A2 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells |
| 01/30/2002 | EP1175489A1 Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same |
| 01/30/2002 | EP1175477A1 Cleaning compositions and tablets |
| 01/30/2002 | EP1175443A1 Modified exendins and exendin agonists |
| 01/30/2002 | EP1175390A1 Disodium salts, monohydrates, and ethanol solvates |
| 01/30/2002 | EP1175235A1 Modified protein matrices |
| 01/30/2002 | EP1175224A2 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy |
| 01/30/2002 | EP1175205A2 Inhibitors of crystallization in a solid dispersion |
| 01/30/2002 | EP1175203A1 Folic acid supplement |
| 01/30/2002 | EP1173153A4 Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants |